Home » Cardio Indication Approved for Diabetes Drug
Cardio Indication Approved for Diabetes Drug
The FDA has approved Novo Nordisk’s Victoza (liraglutide) as a type 2 diabetes drug that reduces the risk of heart attack and stroke.
The drug was approved by the FDA in 2010 for blood-sugar control. The latest approval adds its effect on cardiovascular risk to its benefits.
An injectable, Victoza is approved for adults with diabetes 2 or cardiovascular disease.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May